Gene activated matrices for bone and cartilage regeneration in arthritis

European Journal of Nanomedicine

Volumn 4, Issue 1, 2012, Pages 17-32

  Plank, Christian ^a   Eglin, David ^b   Fahy, Niamh ^c   Sapet, Cedric ^d   Borget, Pascal ^e   Van Osch, Gerjo ^f   Gentili, Chiara ^g   Miramond, Thomas ^h   Zöller, Katharina ⁱ   Anton, Martina ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b AO RESEARCH INSTITUTE   (Switzerland)

^c NATIONAL UNIVERSITY OF IRELAND   (Ireland)

^d OZ Biosciences   (France)

^e Biomatlante SA   (France)

^f ERASMUS MEDICAL CENTER   (Netherlands)

^g UNIVERSITY OF GENOA   (Italy)

^h INSERM   (France)

ⁱ Maren Schüpphaus and Sven Siebert GbR ^*  (Germany)

Author keywords

Citizen participation in science; Gene activated matrices; Gene vectors; Hyaluronan hydrogel; Mesenchymal stem cells; Micro macroporous biphasic calcium phosphate; Spatiotemporal control

Indexed keywords

CITIZEN PARTICIPATION; GENE VECTORS; HYALURONAN HYDROGELS; MESENCHYMAL STEM CELL; MICRO MACROPOROUS BIPHASIC CALCIUM PHOSPHATES; SPATIOTEMPORAL CONTROL;

BIOACTIVITY; BIOMATERIALS; BIOMIMETICS; BONE; CARTILAGE; CELL CULTURE; FUNCTIONAL POLYMERS; INNOVATION; NANOPARTICLES; TISSUE; VECTORS;

GENE EXPRESSION;

ATELOCOLLAGEN; BIOMIMETIC MATERIAL; COPOLYMER; DOXYCYCLINE; MAGNETIC NANOPARTICLE; MICRO MACROPOROUS BIPHASIC CALCIUM PHOSPHATE; TETRACYCLINE; UNCLASSIFIED DRUG;

BONE REGENERATION; BONE REMODELING; CARTILAGE MATRIX; CONFERENCE PAPER; GENE ACTIVATED MATRIX; GENE EXPRESSION REGULATION; GENE VECTOR; HEAT; HUMAN; HYDROGEL; MESENCHYMAL STEM CELL; NONHUMAN; OSTEOARTHRITIS; SYNTHESIS; TEMPERATURE SENSITIVITY; TISSUE REPAIR;

EID: 84867844344     PISSN: 16625986     EISSN: 1662596X     Source Type: Journal    
DOI: 10.1515/ejnm-2012-0001     Document Type: Conference Paper

References (75)

1. Statistics on hospital-based care in the United States, 2009: Department of Health and Human Services USA 2009. http://www.hcup-us.ahrq.gov/reports/ factsandfigures/2009/pdfs/FF-report-2009.pdf. Accessed February 27, 2012.
2. Vasara AI, Konttinen YT, Peterson L, Lindahl A, Kiviranta I. Persisting high levels of synovial fluid markers after cartilage repair. Clin Orthop Relat Res 2009;467:267-72.
3. Dunlop DD, Manheim LM, Yelin EH, Song J, Chang RW. The costs of arthritis. Arthritis Rheum 2003;49:101-13. (Pubitemid 36286136)
4. A.E.P. Limited. Painful realities: the economic impact of arthritis in Australia, 2007. Canberra: Arthritis Australia 2007. http://www. arthritisaustralia.com.au/images/stories/documents/reports/2011-updates/ Painful-Realities-executive-summary-Access-Economics.pdf. Accessed February 27, 2012.
5. Helmick CG, Felson DT, Lawrence RC, Gabriel S, Hirsch R, Kwoh CK, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States: Part I. Arthritis Rheum 2008;58:15-25.
6. Lawrence RC, Felson DT, Helmick CG, Arnold LM, Choi H, Deyo RA, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States: Part II. Arthritis Rheum 2008;58:26-35.
7. Gesundheit-Krankheitskosten 2002, 2004, und 2008. Wiesbaden, Germany, 2010. http://www.destatis.de/jetspeed/portal/cms/Sites/destatis/Internet/DE/ Content/Publikationen/Fachveroeffentlichungen/Gesundheit/Krankheitskosten/ Krankhei tskosten2120720089004,property=file.pdf. Accessed February 27, 2012.
8. Merx H, Dreinhofer KE, Gunther KP. Sozialmedizinische Bedeutung der Arthrose in Deutschland. Z Orthop Unfall 2007; 145:421-9. (Pubitemid 47571625)
9. Carragee EJ, Hurwitz EL, Weiner BK. A critical review of recombinant human bone morphogenetic protein-2 trials in spinal surgery: emerging safety concerns and lessons learned. Spine J 2011;11:471-91.
10. Epstein NE. Pros, cons, and costs of INFUSE in spinal surgery. Surg Neurol Int 2011;2:10.
11. McKay WF, Peckham SM, Badura JM. A comprehensive clinical review of recombinant human bone morphogenetic protein-2 (INFUSE® Bone Graft). Int Orthop 2007;31:729-34. (Pubitemid 350160311)
12. Cohen D. Medtronic submits full data on spinal protein to independent scrutiny. Br Med J 2011;343:d5484.
13. McKay B. Conf Proc IEEE Eng Med Biol Soc 2009; 2009:236.
14. Cao L, Mooney DJ. Spatiotemporal control over growth factor signaling for therapeutic neovascularization. Adv Drug Deliv Rev 2007;59:1340-50. (Pubitemid 350090012)
15. Lee KY, Peters MC, Anderson KW, Mooney DJ. Controlled growth factor release from synthetic extracellular matrices. Nature 2000;408:998-1000. (Pubitemid 32101648)
16. Bonadio J. Tissue engineering via local gene delivery: update and future prospects for enhancing the technology. Adv Drug Deliv Rev 2000;44:185-94.
17. De Laporte L, Shea LD. Matrices and scaffolds for DNA delivery in tissue engineering. Adv Drug Deliv Rev 2007;59:292-307. (Pubitemid 46879971)
18. Shea LD, Smiley E, Bonadio J, Mooney DJ. DNA delivery from polymer matrices for tissue engineering. Nat Biotechnol 1999;17:551-4. (Pubitemid 29262917)
19. Evans CH, Ghivizzani SC, Robbins PD. Orthopedic gene therapy in 2008. Mol Ther 2009;17:231-44.
20. Leach JB, Schmidt CE, Bowlin GL, Wnek G. Hyaluronan. Encyclopedia of biomaterials and biomedical engineering. New York: Marcel Dekker Inc.; 2004. p. 779.
21. Lapcik L Jr, Lapcik L. Hyaluronan: preparation, structure, properties, and applications. Chem Rev 1998;98:2663-84.
22. Crescenzi V, Cornelio L, Di Meo C, Nardecchia S, Lamanna R. Novel hydrogels via click chemistry: synthesis and potential biomedical applications. Biomacromolecules 2007;8:1844-50. (Pubitemid 47009962)
23. Arinzeh TL, Tran T, McAlary J, Daculsi G. A comparative study of biphasic calcium phosphate ceramics for human mesenchymal stem-cell-induced bone formation. Biomaterials 2005;26:3631-8. (Pubitemid 40038157)
24. Daculsi G, Uzel AP, Weiss P, Goyenvalle E, Aguado E. Developments in injectable multiphasic biomaterials. The performance of microporous biphasic calcium phosphate granules and hydrogels. J Mater Sci Mater Med 2010;21:855-61.
25. Daculsi G, Jegoux F, Layrolle P. The micro macroporous biphasic calcium phosphate concept for bone reconstruction and tissue engineering. Advanced Biomaterials. John Wiley & Sons, Inc. Hoboken, NJ, USA; 2010. p. 101.
26. Teixeira CC, Nemelivsky Y, Karkia C, Legeros RZ. Biphasic calcium phosphate: a scaffold for growth plate chondrocyte maturation. Tissue Eng 2006;12:2283.
27. Finsinger D, Remy JS, Erbacher P, Koch C, Plank C. Protective copolymers for nonviral gene vectors: synthesis, vector characterization and application in gene delivery. Gene Ther 2000;7:1183-92. (Pubitemid 30488765)
28. Kolk A, Haczek C, Koch C, Vogt S, Kullmer M, Pautke C, et al. A strategy to establish a gene-activated matrix on titanium using gene vectors protected in a polylactide coating. Biomaterials 2011;32:6850-9.
29. Reckhenrich AK, Hopfner U, Krotz F, Zhang Z, Koch C, Kremer M, et al. Bioactivation of dermal scaffolds with a nonviral copolymer-protected gene vector. Biomaterials 2011;32: 1996-2003.
30. Scherer F, Schillinger U, Putz U, Stemberger A, Plank C. Nonviral vector loaded collagen sponges for sustained gene delivery in vitro and in vivo . J Gene Med 2002;4:634-43. (Pubitemid 40277187)
31. Schillinger U, Wexel G, Hacker C, Kullmer M, Koch C, Gerg M, et al. A fibrin glue composition as carrier for nucleic acid vectors. Pharm Res 2008;25:2946-62.
32. Subr V, Kostka L, Selby-Milic T, Fisher K, Ulbrich K, Seymour LW, et al. Coating of adenovirus type 5 with polymers containing quaternary amines prevents binding to blood components. J Control Release 2009;135:152-8.
33. Rachakonda PS, Rai MF, Schmidt MF. Application of inflammation-responsive promoter for an in vitro arthritis model. Arthritis Rheum 2008;58:2088-97. (Pubitemid 351988100)
34. Deckers R, Quesson B, Arsaut J, Eimer S, Couillaud F, Moonen CT. Image-guided, noninvasive, spatiotemporal control of gene expression. Proc Natl Acad Sci USA 2009;106:1175-80.
35. Ueblacker P, Wagner B, Kruger A, Vogt S, DeSantis G, Kennerknecht E, et al. Inducible nonviral gene expression in the treatment of osteochondral defects. Osteoarthr Cartilage 2004;12:711-9. (Pubitemid 39172747)
36. Plank C, Zelphati O, Mykhaylyk O. Magnetically enhanced nucleic acid delivery. Ten years of magnetofection-Progress and prospects. Adv Drug Deliv Rev 2011;63:1300-31.
37. Maier-Hauff K, Ulrich F, Nestler D, Niehoff H, Wust P, Thiesen B, et al. Efficacy and safety of intratumoral thermotherapy using magnetic iron-oxide nanoparticles combined with external beam radiotherapy on patients with recurrent glioblastoma multiforme. J Neurooncol 2011;103:317-24.
38. Ortner V, Kaspar C, Halter C, Töllner L, Mykhaylyk O, Walzer J, et al. J Control Release. doi: 10.1016/j.jconrel.2011.12.006.
39. Cancedda R, Castagnola P, Cancedda FD, Dozin B, Quarto R. Int J Dev Biol 2000;44:707.
40. Muraglia A, Cancedda R, Quarto R. J Cell Sci 2000;113(Pt 7):1161.
41. Quarto R, Mastrogiacomo M, Cancedda R, Kutepov SM, Mukhachev V, Lavroukov A, et al. Repair of large bone defects with the use of autologous bone marrow stromal cells. N Engl J Med 2001;344:385-6. (Pubitemid 32107654)
42. Giannoni P, Mastrogiacomo M, Alini M, Pearce SG, Corsi A, Santolini F, et al. Regeneration of large bone defects in sheep using bone marrow stromal cells. J Tissue Eng Regen Med 2008;2:253-62.
43. Pittenger M, Vanguri P, Simonetti D, Young R. J Musculoskelet Neuronal Interact 2002;2:309.
44. Mackay AM, Beck SC, Murphy JM, Barry FP, Chichester CO, Pittenger MF. Chondrogenic differentiation of cultured human mesenchymal stem cells from marrow. Tissue Eng 1998;4:415.
45. Johnstone B, Hering TM, Caplan AI, Goldberg VM, Yoo JU. In vitro chondrogenesis of bone marrow-derived mesenchymal progenitor cells. Exp Cell Res 1998;238:265-72. (Pubitemid 28366150)
46. Mastrogiacomo M, Cancedda R, Quarto R. Osteoarthritis Cartilage 2001;9(Suppl A):S36.
47. Murphy JM, Fink DJ, Hunziker EB, Barry FP. Stem cell therapy in a caprine model of osteoarthritis. Arthritis Rheum 2003;48:3464-74. (Pubitemid 37531912)
48. Wakitani S, Imoto K, Yamamoto T, Saito M, Murata N, Yoneda M. Human autologous culture expanded bone marrow mesenchymal cell transplantation for repair of cartilage defects in osteoarthritic knees. Osteoarthr Cartilage 2002;10:199-206. (Pubitemid 34189569)
49. Muraglia A, Corsi A, Riminucci M, Mastrogiacomo M, Cancedda R, Bianco P, et al. Formation of a chondro-osseous rudiment in micromass cultures of human bone-marrow stromal cells. J Cell Sci 2003;116:2949-55. (Pubitemid 36926984)
50. Farrell E, van der Jagt OP, Koevoet W, Kops N, van Manen CJ, Hellingman CA, et al. Chondrogenic priming of human bone marrow stromal cells: a better route to bone repair ? Tissue Eng Part C Methods 2009;15:285.
51. Sanchez-Antequera Y, Mykhaylyk O, van Til NP, Cengizeroglu A, de Jong JH, Huston MW, et al. Magselectofection: an integrated method of nanomagnetic separation and genetic modification of target cells. Blood 2011;117:e171-81.
52. Sapet C, Pellegrino C, Laurent N, Sicard F, Zelphati O. Pharm Res 2011. doi: 10.1007/s11095-011-0629-9.
53. Fisher KD, Stallwood Y, Green NK, Ulbrich K, Mautner V, Seymour LW. Polymer-coated adenovirus permits efficient retargeting and evades neutralising antibodies. Gene Ther 2001;8:341-8. (Pubitemid 32241933)
54. Kreppel F, Kochanek S. Modification of adenovirus gene transfer vectors with synthetic polymers: a scientific review and technical guide. Mol Ther 2008;16:16-29.
55. Rohmer S, Mainka A, Knippertz I, Hesse A, Nettelbeck DM. Insulated hsp70B' promoter: stringent heat-inducible activity in replication-deficient, but not replication-competent adenoviruses. J Gene Med 2008;10:340-54. (Pubitemid 351517090)
56. Anton M, Wolf A, Mykhaylyk O, Koch C, Gansbacher B, Plank C. Pharm Res, 2011. doi: 10.1007/s11095-011-0631-2; Dec 30. [Epub ahead of print].
57. Inoue H, Nanayama T, Hara S, Yokoyama C, Tanabe T. The cyclic AMP response element plays an essential role in the expression of the human prostaglandin-endoperoxide synthase 2 gene in differentiated U937 monocytic cells. FEBS Lett 1994;350:51-4. (Pubitemid 24261395)
58. Inoue H, Yokoyama C, Hara S, Tone Y, Tanabe T. Transcriptional regulation of human prostaglandin-endoperoxide synthase-2 gene by lipopolysaccharide and phorbol ester in vascular endothelial cells. J Biol Chem 1995;270:24965-71.
59. Palmer GD, Stoddart MJ, Gouze E, Gouze JN, Ghivizzani SC, Porter RM, et al. A simple, lanthanide-based method to enhance the transduction efficiency of adenovirus vectorsLa-enhanced adenoviral transduction. Gene Ther 2008;15:357-63. (Pubitemid 351267377)
60. Yang N, Zhang W, Shi XM. Glucocorticoid-induced leucine zipper (GILZ) mediates glucocorticoid action and inhibits inflammatory cytokine-induced COX-2 expression. J Cell Biochem 2008;103:1760-71. (Pubitemid 351501908)
61. Urlinger S, Baron U, Thellmann M, Hasan MT, Bujard H, Hillen W. Exploring the sequence space for tetracycline-dependent transcriptional activators: novel mutations yield expanded range and sensitivity. Proc Natl Acad Sci USA 2000;97: 7963-8. (Pubitemid 30460756)
62. Benoit DS, Schwartz MP, Durney AR, Anseth KS. Small functional groups for controlled differentiation of hydrogelencapsulated human mesenchymal stem cells. Nat Mater 2008;7:816-23.
63. Smith AE, Xu X, McCormick CL. Stimuli-responsive amphiphilic (co)polymers via RAFT polymerization. Prog Polym Sci 2010;35:45-93.
64. Mortisen D, Peroglio M, Alini M, Eglin D. Tailoring thermoreversible hyaluronan hydrogels by " click " chemistry and RAFT polymerization for cell and drug therapy. Biomacromolecules 2010;11:1261-72.
65. Lee K, Silva EA, Mooney DJ. Growth factor delivery-based tissue engineering: general approaches and a review of recent developments. J R Soc Interface 2011;8:153-70.
66. Gojgini S, Tokatlian T, Segura T. Utilizing cell-matrix interactions to modulate gene transfer to stem cells inside hyaluronic acid hydrogels. Mol Pharm 2011;8:1582-91.
67. Aguado B, Mulyasasmita W, Su J, Lampe KJ, Heilshorn S. Improving viability of stem cells during syringe needle flow through the design of hydrogel cell carriers. Tissue Eng Part A 2011;18:806-15.
68. Honig D, DeRouchey J, Jungmann R, Koch C, Plank C, Radler JO. Biophysical characterization of copolymer-protected gene vectors. Biomacromolecules 2010;11:1802-9.
69. Faensen B, Wildemann B, Hain C, Hohne J, Funke Y, Plank C, et al. Local application of BMP-2 specific plasmids in fibrin glue does not promote implant fixation. BMC Musculoskelet Disord 2011;12:163.
70. Cals FL, Hellingman CA, Koevoet W, Baatenburg de Jong RJ, van Osch GJ. Effects of transforming growth factor-β subtypes on in vitro cartilage production and mineralization of human bone marrow stromal-derived mesenchymal stem cells. J Tissue Eng Regen Med 2012;6:68-76.
71. de Vries-van Melle ML, Mandl EW, Kops N, Koevoet WJ, Verhaar JA, van Osch GJ. An osteochondral culture model to study mechanisms involved in articular cartilage repair. Tissue Eng Part C Methods 2012;18:45-53.
72. Goshima J, Goldberg VM, Caplan AI. Clin Orthop Relat Res 1991;274.
73. Goshima J, Goldberg VM, Caplan AI. Clin Orthop Relat Res 1991;298.
74. Martin I, Muraglia A, Campanile G, Cancedda R, Quarto R. Fibroblast growth factor-2 supports ex vivo expansion and maintenance of osteogenic precursors from human bone marrow. Endocrinology 1997;138:4456-62. (Pubitemid 27408494)
75. Tortelli F, Pujic N, Liu Y, Laroche N, Vico L, Cancedda R. Osteoblast and osteoclast differentiation in an in vitro three-dimensional model of bone. Tissue Eng Part A 2009;15:2373-83.